Literature DB >> 17363579

p53-independent abrogation of a postmitotic checkpoint contributes to human papillomavirus E6-induced polyploidy.

Yingwang Liu1, Susan A Heilman, Diego Illanes, Greenfield Sluder, Jason J Chen.   

Abstract

Polyploidy is often an early event during cervical carcinogenesis, and it predisposes cells to aneuploidy, which is thought to play a causal role in tumorigenesis. Cervical and anogenital cancers are induced by the high-risk types of human papillomavirus (HPV). The HPV E6 oncoprotein induces polyploidy in human keratinocytes, yet the mechanism is not known. It was believed that E6 induces polyploidy by abrogating the spindle checkpoint after mitotic stress. We have tested this hypothesis using human keratinocytes in which E6 expression induces a significant amount of polyploidy. We found that E6 expression does not affect the spindle checkpoint. Instead, we provide direct evidence that E6 is capable of abrogating the subsequent G(1) arrest after adaptation of the mitotic stress. E6 targets p53 for degradation, and previous studies have shown an important role for p53 in modulation of the G(1) arrest after mitotic stress. Importantly, we have discovered that E6 mutants defective in p53 degradation also induce polyploidy, although with lower efficiency. These results suggest that E6 is able to induce polyploidy via both p53-dependent and p53-independent mechanisms. Therefore, our studies highlight a novel function of HPV E6 that may contribute to HPV-induced carcinogenesis and improve our understanding of the onset of the disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363579     DOI: 10.1158/0008-5472.CAN-06-3436

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  Levels of the E2 interacting protein TopBP1 modulate papillomavirus maintenance stage replication.

Authors:  Sriramana Kanginakudru; Marsha DeSmet; Yanique Thomas; Iain M Morgan; Elliot J Androphy
Journal:  Virology       Date:  2015-02-07       Impact factor: 3.616

3.  Abrogation of the postmitotic checkpoint contributes to polyploidization in human papillomavirus E7-expressing cells.

Authors:  Susan A Heilman; Joshua J Nordberg; Yingwang Liu; Greenfield Sluder; Jason J Chen
Journal:  J Virol       Date:  2009-01-07       Impact factor: 5.103

Review 4.  Papillomavirus E6 oncoproteins.

Authors:  Scott B Vande Pol; Aloysius J Klingelhutz
Journal:  Virology       Date:  2013-05-24       Impact factor: 3.616

5.  ZNF365 promotes stalled replication forks recovery to maintain genome stability.

Authors:  Yuqing Zhang; Eunmi Park; Christopher S Kim; Ji-hye Paik
Journal:  Cell Cycle       Date:  2013-08-06       Impact factor: 4.534

6.  Role of Cdk1 in DNA damage-induced G1 checkpoint abrogation by the human papillomavirus E7 oncogene.

Authors:  Xueli Fan; Jason J Chen
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  Genomic Instability Induced By Human Papillomavirus Oncogenes.

Authors:  Jason J Chen
Journal:  N Am J Med Sci (Boston)       Date:  2010-04

8.  Human papillomavirus E7 induces rereplication in response to DNA damage.

Authors:  Xueli Fan; Yingwang Liu; Susan A Heilman; Jason J Chen
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

9.  The human papillomavirus type 58 E7 oncoprotein modulates cell cycle regulatory proteins and abrogates cell cycle checkpoints.

Authors:  Weifang Zhang; Jing Li; Sriramana Kanginakudru; Weiming Zhao; Xiuping Yu; Jason J Chen
Journal:  Virology       Date:  2009-11-27       Impact factor: 3.616

10.  Role of Cdc6 in re-replication in cells expressing human papillomavirus E7 oncogene.

Authors:  Xueli Fan; Yunying Zhou; Jason J Chen
Journal:  Carcinogenesis       Date:  2016-05-06       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.